"IIL Invests ₹700 Crore in State-of-the-Art Vaccine Plant to Tackle Livestock Diseases"

Indian Immunologicals (IIL), a biotechnology company operating under the National Dairy Development Board (NDDB), announced on Thursday the commencement of construction for its cutting-edge vaccine manufacturing plant in Genome Valley, Hyderabad. With an investment of approximately Rs. 700 crore, the facility marks a significant step in bolstering India's capabilities in combating livestock diseases.

The new plant is equipped with a state-of-the-art BSL3 (biosafety level) facility for drug substance production, along with a Fill-Finish capability dedicated to final vaccine products. The primary focus of the unit is to address two major livestock diseases: Foot and Mouth Disease (FMD) and Haemorrhagic Septicaemia (HS). The annual production capacity of the facility is set at an impressive 150 million doses for each vaccine, totaling 300 million doses.

Apart from its critical role in vaccine production, the new facility is expected to generate over 750 direct and indirect job opportunities. Positioned strategically within Genome Valley, IIL aims to lead India's biotechnology advancements, contributing to Hyderabad's global reputation as a hub for vaccine innovation and production.

Meenesh Shah, Chairman of NDDB, emphasized the facility's significance in eradicating FMD and HS within the country, reaffirming IIL's commitment to its mission. K Anand Kumar, Managing Director of IIL, echoed this sentiment, noting the company's critical growth phase and anticipating a 40% increase in the coming year. He highlighted the facility's role in enabling further investments, contributing to disease control and eradication efforts not only in India but also across emerging markets.

BS